Compare HIPO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | MNKD |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | 540 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.8M | 793.6M |
| IPO Year | N/A | 2004 |
| Metric | HIPO | MNKD |
|---|---|---|
| Price | $26.25 | $2.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $38.67 | $8.69 |
| AVG Volume (30 Days) | 71.6K | ★ 3.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $28.28 | $35.81 |
| Revenue Next Year | $22.33 | $11.89 |
| P/E Ratio | ★ $7.64 | $137.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $19.92 | $2.23 |
| 52 Week High | $38.98 | $6.51 |
| Indicator | HIPO | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 51.93 |
| Support Level | $24.85 | $2.52 |
| Resistance Level | $27.12 | $2.98 |
| Average True Range (ATR) | 0.93 | 0.13 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 40.48 | 63.53 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.